Navigation Links
Genzyme Delivers Strong Fourth Quarter to Conclude Outstanding Year
Date:2/13/2008

impact of such approvals on the company; its plans and estimated timetables for new and next-generation product filings, approvals and launches, including for Mozobil, Clolar, alemtuzumab-MS, mipomersen, Genz- 112638 and Synvisc-ONE and the assessment of the market potential of such products and product candidates; its projected SG&A and R&D expenses as a percentage of revenues in 2008; its expected tax rate for 2008; its expected capital expenditures for 2008; and its expected time line for securing approval for Myozyme manufacturing at its Belgium facility. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those forecasted. These risks and uncertainties include, among others: Genzyme's ability to successfully complete preclinical and clinical development of its products and product candidates, including Mozobil, Clolar, alemtuzumab-MS, mipomersen, Genz-112638; Genzyme's ability to expand the use of current and next-generation products in existing and new indications, including Synvisc-ONE and Renvela; Genzyme's ability to obtain and maintain regulatory approvals for products and manufacturing facilities, including the larger-scale production of Myozyme and the timing of receipt of such approvals; Genzyme's ability to manufacture products and product candidates in a timely and cost effective manner and in sufficient quantities to meet demand; Genzyme's ability to maintain and enforce intellectual property rights; Genzyme's ability to successfully identify and market to new patients; the scope of third-party reimbursement coverage for Genzyme's products and services; and the risks and uncertainties described in Genzyme's SEC reports filed under the Securities Exchange Act of 1934, including the factors discussed under the caption "Risk Factors" in Genzyme's Quarterly Report on Form 10-Q for the period ended September 30, 2007. Genzyme cautions investors not to place substantial reliance on the forward-
'/>"/>
SOURCE Genzyme Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24

Related medicine news :

1. Genzyme Receives FDA Response Letter on Synvisc-One(TM)
2. Bioenvision Shareholders Approve Acquisition by Genzyme Corporation
3. Genzyme Statement Regarding Results of FDA Advisory Committee Meeting on the Use of Phosphate Binders in Chronic Kidney Disease
4. Genzyme and Bayer Schering Pharma AG, Germany to Present New Data on Alemtuzumab in Multiple Sclerosis at ECTRIMS
5. Delaware Court Approves Bioenvision, Genzyme Joint Petition
6. Elliott Extremely Dissatisfied With Genzyme Bid for Bioenvision; Believes Offer Significantly Undervalues Company
7. Liquent Insight Publisher 3.6 Delivers Advanced Submission Capabilities
8. March of Dimes Delivers a New Look
9. Independence Blue Cross Delivers Important Reminder to Women during Cervical Cancer Awareness Month
10. PARIs eFlow Delivers Alnylam RNAi Therapeutic in Phase I Study
11. Gleevec, the targeted cancer pill, delivers more good news to patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2014)... July 13, 2014 Celebrity fitness trainer ... formed a promotional partnership with Aqua Health Labs for ... Omega-3 EPA supplement . The collaboration was recently announced ... fitness trainer , actor, model, and a two ... for A-List celebrities, he has prepared stars including Demi ...
(Date:7/13/2014)... Hope Palliative & Hospice Care announced today ... at the Tamarack Senior Living Community in Palatine, IL. The ... on the 3rd Wednesdays of every month. This group ... Community located at 55 S. Greeley St. Palatine, IL 60067. ... is no cost for the group. , “A grief ...
(Date:7/13/2014)... According to The Peripheral Neuropathy Program review ... that teaches people how to deal with diabetic nerve ... This program also provides people with safe and effective ... including numbness, prickling, burning, and intense stabbing pains. ... treatment program can help people eliminate some types of ...
(Date:7/13/2014)... Recently, iFitDress.com, one of the most popular suppliers of ... a new selection of beautiful evening dresses ... promotion for these evening gowns. Now, everybody can enjoy ... thousands of graceful gowns in its online store. Most ... Italy and many other countries. They are highly appreciated ...
(Date:7/12/2014)... 13, 2014 Recently, Fadhits.com, a well-known wedding ... elegant long graduation dresses to its product line. ... its loyal clients. It wants to bring more benefits for ... now offered at discounted prices, up to 72% off. , ... always working hard. Its online shop is a good place ...
Breaking Medicine News(10 mins):Health News:Celebrity Fitness Expert Supports Revolutionary New Health Supplement 2Health News:Hope Hospice Announces Grief Support Group at the Tamarack Senior Living Community 2Health News:The Peripheral Neuropathy Program Review Exposes Randall Labrum's Peripheral Neuropathy Treatment Program – Vkool.com 2Health News:The Peripheral Neuropathy Program Review Exposes Randall Labrum's Peripheral Neuropathy Treatment Program – Vkool.com 3Health News:New and Beautiful Evening Dresses Unveiled by iFitDress.com 2Health News:New Collection of Long Graduation Dresses Revealed by Fadhits.com 2
... Life-DaVita Medical Missions, program reaches out to patients in ... need of care ... program is being recognized as life-saving by 16 year-old,Juan Carlos and his ... for survival and was just days away from dying.,This past December, DaVita ...
... studies finds regimen popular in 1980s doesn,t really lengthen ... chemotherapy has only a minimal effect on survival in ... , "It,s pretty clearly established that [high-dose chemotherapy] is ... of the Division of Quantitative Sciences at the University ...
... The fifth annual Gastrointestinal Cancers Symposium is a three-day ... on the latest clinical strategies for the prevention, screening ... are expected to gather at this years Symposium which ... Friday, January 25 Sunday, January 27, 2008, WHERE:, ...
... and Leicester are collaborating in the use of a ... spaces inside the lungs and the results of ... disease and later degenerative lung disease. , There are ... to this particular magnetic resonance technique, which is based ...
... Boston, MAMichael F. Holick, PhD, MD, was recently awarded ... Society of Endocrinology and Metabolism (CSEM). Holick, an ... received the award for decades of pioneering work that ... wide variety of chronic health conditions. , ...
... A clinical study conducted at Henry Ford Hospital on ... patients with the most common and aggressive type of brain ... , The randomized Phase II study focused on patients ... or second-line therapy. The study revealed that more than a ...
Cached Medicine News:Health News:16-Year-Old Ecuadorian Boy in Dire Need of Dialysis Treatments Thanks One of Nation's Leading Providers for Saving His Life 2Health News:16-Year-Old Ecuadorian Boy in Dire Need of Dialysis Treatments Thanks One of Nation's Leading Providers for Saving His Life 3Health News:High-Dose Chemo Provides Little Benefit to Breast Cancer Patients 2Health News:High-Dose Chemo Provides Little Benefit to Breast Cancer Patients 3Health News:New technique reveals insights into lung disease 2Health News:Boston University Medical Center researcher honored 2Health News:Drug study for brain cancer shows promising results 2
(Date:7/11/2014)... Research and Markets ( http://www.researchandmarkets.com/research/tjlw9k/immunoprotein ) ... Diagnostic Testing Market - Forecasts to 2019: Expected ... and is expected to be valued at USD ... http://photos.prnewswire.com/prnh/20130307/600769 ... segmented according to immunoprotein types which include immunoglobulins, ...
(Date:7/10/2014)... 11. Juli 2014  Dilon Technologies, ... die molekulare Bildgebung, einschließlich molekularer Bildgebung ... CE-Zulassung für sein Navigator ® -Gamma-Sondensystem ... das Produkt jetzt europaweit vertreiben. Dilon ... der europäischen Länder ausgedehnt und bereits ...
(Date:7/10/2014)... 2014 Yesterday, former Congressman Patrick ... manufacturing facility. Rep. Kennedy and Dick Moberg ... cutting-edge research in neurological disease and treatment. ... advocate, Garen Staglin , created One Mind, ... changes that will radically accelerate the development and ...
Breaking Medicine Technology:Immunoprotein Diagnostic Testing Market - Forecasts to 2019: Expected to grow at the highest CAGR of 6% and is expected to be valued at USD 4,943.0 million 2Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2Representative Patrick Kennedy visits Moberg's medical device facility to discuss improvement in brain injury care 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: